Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group



Status:Completed
Conditions:Diabetes, Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - 75
Updated:1/27/2017
Start Date:February 2001
End Date:October 2001

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

NNC 90-1170 Mechanism of Action: A Double-blind, Randomized, Single-center, Placebo Controlled, Crossover Study to Examine Beta-cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes

This trial is conducted in the United States of America (USA). The aim of this trial is to
assess the effect of NNC 90-1170 on beta-cell responsiveness to increasing blood glucose
concentrations in subjects with type 2 diabetes.


Inclusion Criteria:

- Diagnosed with type 2 diabetes, either newly diagnosed with at least 2 months of diet
or on OAD monotherapy for at least 3 months

- Body Mass Index (BMI): 24-35 kg/m^2 inclusive

Exclusion Criteria:

- SUBJECTS WITH TYPE 2 DIABETES

- Receipt of any investigational drug within three months prior to this trial

- Recurrent severe hypoglycemia as judged by the investigator

- Cardiac disease

- Use of any drug (except an OAD (oral anti-diabetic drug)) that in the investigator's
opinion could interfere with the blood glucose level

- Haemoglobin maximum 10 g/L

- HbA1c above 12%

- Loss of more than 400 mL blood during the 3 months prior to trial start

- HEALTHY SUBJECTS

- Receipt of any investigational drug within 3 months prior to this trial

- Clinically relevant cardiac disease or any clinically significant abnormal ECG
(electrocardiogram)

- Use of any drug that in the investigator's opinion could interfere with the blood
glucose level

- Haemoglobin max. 10 g/L

- HbA1c at least 6%
We found this trial at
1
site
Novo Nordisk Investigational Site
Ann Arbor, Michigan 48106
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials